The Innovation Process for Biotechnology-based New Drug Development: Why is the New Drug Market Getting Smaller?

DOI

Bibliographic Information

Other Title
  • バイオテクノロジーを用いた新薬開発のイノベーションプロセス
  • ―なぜ、新薬市場は小規模化するのか―

Description

<p>New drug development in recent years has shifted to new types of compounds, such as biopharmaceuticals and molecular-target drugs, but the market size for these types of drugs tends to be smaller. The transition to biopharmaceuticals and molecular-target drugs development is a high-risk choice, with high development and manufacturing costs, significantly higher switching costs, yet no less development uncertainty. Nonetheless, it seems to contradict the general concept of product innovation that the market size for new drugs should be smaller.</p><p>An examination of drug development cases in the field of lung cancer over the last 20 years reveals change in the drug development process whereby drug development proceeds in the interaction of the three trends: more precise therapeutic targets, the emergence of biopharmaceuticals and molecular-target drugs, and the limitation of patient indication, in line with the social shaping of technology, when the condition of increased clinical value is met. The downsizing of new drug markets can be viewed as one aspect of the drug development process.</p>

Journal

  • Journal of Innovation Management

    Journal of Innovation Management 21 (0), 161-177, 2024-03-31

    The Research Institute for Innovation Management of Hosei University

Keywords

Details 詳細情報について

  • CRID
    1390299673817734016
  • DOI
    10.24677/riim.21.0_161
  • ISSN
    24336971
    13492233
  • Text Lang
    ja
  • Data Source
    • JaLC
  • Abstract License Flag
    Disallowed

Report a problem

Back to top